Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
The Clinical Study of Mycophenolate Mofetil in Pediatric Refractory Gastrointestinal Henoch-Schonlein Purpura
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Haiyan Wang, MD
- Phone Number: +8613560489257
- Email: wanghy78@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Contact:
- Haiyan Wang, MD
- Phone Number: 8613560489257
- Email: wanghy78@mail.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages range from 3 to 18 years old;
- Patients who meet the diagnostic criteria for HSP and involve the digestive tract: acute diffuse abdominal colic, including intussusception and gastrointestinal bleeding, appears during the course of the disease or is found on physical examination;
- Refractory gastrointestinal type HSP: treated with Intravenous corticosteroid 2 mg/kg/d for 3 days without effecacy or relapsed during the attenuation of corticosteroid
- Parents or guardians agree to treatment and sign a written informed consent form.
Exclusion Criteria:
- Patients who are allergic to MMF;
- Patients with severe diseases: such as systemic malignancies, heart failure, liver and renal failure, Immune deficiency, severe infectious diseases, organ transplant surgery, or other current indications for emergency surgery;
- Patients with other digestive system diseases;
- Those who have previously used MMF clinical trials;
- Other situations the researcher thought inappropriate to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: mycophenolate mofetil in refractory gastrointestinal Henoch-Schönlein purpura
patients who were resistant to steroid were treated with MMF
|
MMF treat refractory gastrointestinal Henoch-Schönlein purpura
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Abdominal pain, hematemesis and bloody stools
Time Frame: 6 months
|
assessed by checklist
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
count of red blood cells in Stool
Time Frame: 6 months
|
Test for every week
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Weiping Tan, PhD, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immune System Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Hemostatic Disorders
- Vasculitis
- Skin Diseases, Vascular
- Hypersensitivity
- Blood Coagulation Disorders
- Skin Manifestations
- Immune Complex Diseases
- Purpura
- IgA Vasculitis
Other Study ID Numbers
Other Study ID Numbers
- 2019-KY-021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.